Insider Trading Alert - OPK, CLX And CYN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 19, 2014, 107 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $699.00 to $189,034,125.00.

Highlighted Stocks Traded by Insiders:

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 20,500 shares at $9.95 on March 19, 2014. Following this transaction, the CEO & Chairman owned 139.6 million shares meaning that the stake was reduced by 0.01% with the 20,500-share transaction.

The shares most recently traded at $9.74, down $0.21, or 2.16% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 3.2 million shares per day over the past 30 days. Opko Health has a market cap of $4.1 billion and is part of the health care sector and health services industry. Shares are up 15.17% year-to-date as of the close of trading on Wednesday.

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Blame the Millennials: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Biotech Movers: Paratek, Opko, Endo

Insiders Are Loading Up on GE, Twilio & More

Ford Motor, Constellation Brands, Cypress Semiconductor: 'Mad Money' Lightning Round